Humanigen Inc (fka HGENQ)

[AC11]

I’m not saying the results are great in this post; I’m just pointing out how the study was being interpreted very incorrectly and showing why you make can numbers say whatever you want if you don’t use them properly.

All we can say at this point is that the data in the case-control study is compelling for the efficacy of lenzilumab.

If the phase 3 study is filling fast, more patients enrolled means less of a difference is needed to show statistical significance. So it makes sense to forego the interim analysis to me if a pause was needed to complete it. It sounds like that pause could be as long as the time needed to fully enroll the trial, and if that’s the case, why not continue? I’m not 100% clear on the details of the pause though as I missed that conference call.